Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Karuna Therapeutics, Inc.
Karuna Therapeutics, Inc. News
Feb 23, 2024 - zacks.com
Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout
Feb 22, 2024 - businesswire.com
Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
Feb 14, 2024 - businesswire.com
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX
Jan 10, 2024 - zacks.com
Bullish Continuation in '24? 3 Market Areas to Watch
Karuna Therapeutics, Inc. Quantitative Score
About Karuna Therapeutics, Inc.
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Karuna Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Karuna Therapeutics, Inc. Financials
Table Compare
Compare KRTX metrics with: | |||
|---|---|---|---|
Earnings & Growth | KRTX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | KRTX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | KRTX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | KRTX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Karuna Therapeutics, Inc. Income
Karuna Therapeutics, Inc. Balance Sheet
Karuna Therapeutics, Inc. Cash Flow
Karuna Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Sell |
| Return on Assets | Neutral |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Karuna Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Dr. Andrew Craig Miller Ph.D. | Founder and President of Research & Development |
| Dr. Stephen K. Brannan | Chief Medical Officer |
| Ms. Mia Kelley J.D. | General Counsel |
| Mr. William Meury | President, Chief Executive Officer & Director |
| Mr. Frank Truslow | Senior Vice President of Corporate Development |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Andrew Craig Miller Ph.D. | Founder and President of Research & Development | 1982 | 835.4K | |
| Dr. Stephen K. Brannan | Chief Medical Officer | 1956 | 751.75K | |
| Ms. Mia Kelley J.D. | General Counsel | Female | -- | |
| Mr. William Meury | President, Chief Executive Officer & Director | Male | 1968 | -- |
| Mr. Frank Truslow | Senior Vice President of Corporate Development | Male | -- |
Karuna Therapeutics, Inc. Insider Trades
| Date | 18 Mar |
| Name | Wheadon David E. |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 990 |
| Date | 18 Mar |
| Name | Wheadon David E. |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 25000 |
| Date | 18 Mar |
| Name | Wheadon David E. |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 8500 |
| Date | 18 Mar |
| Name | Wheadon David E. |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 5000 |
| Date | 18 Mar |
| Name | Wheadon David E. |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 1904 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 18 Mar | Wheadon David E. | Director | Disposed | D-Return | 990 |
| 18 Mar | Wheadon David E. | Director | Disposed | D-Return | 25000 |
| 18 Mar | Wheadon David E. | Director | Disposed | D-Return | 8500 |
| 18 Mar | Wheadon David E. | Director | Disposed | D-Return | 5000 |
| 18 Mar | Wheadon David E. | Director | Disposed | D-Return | 1904 |